<DOC>
	<DOCNO>NCT01824485</DOCNO>
	<brief_summary>Viscosupplementation intra-articular injection hyaluronate product recently gain popularity treatment modality gonarthritis.There , however , consensus best method.Our objective evaluate best dosage viscosupplementation hyaluronic acid ( OSTEONIL® ) associate 1 ml ( 20 mg ) triamcinolone hexacetonide . One hundred four patient knee osteoarthritis ( KOA ) divide 2 group 52 patient receive either single application 3 ampoule OSTEONIL® + 1ml Hexacetonide triamcinolone three application 1 ampoule OSTEONIL® , one per week three week + 1ml Hexacetonide triamcinolone first injection . Primary endpoint clinical result express Visual Analogic Scale pain ( VAS ) , Western Ontario Mcmaster Universities ( WOMAC ) Lequesne questionaires one , three , six 12 month procedure</brief_summary>
	<brief_title>Comparison Two Application Regimens Viscosupplementation</brief_title>
	<detailed_description>Viscosupplementation intra-articular injection hyaluronate product recently gain popularity treatment modality gonarthritis . Hyaluronic Acid responsible elasticity viscosity synovial fluid , protect joint . Biopsy study show besides gain pain function , viscosupplementation may lead structural change cartilage . Currently several study effect intra-articular injection hyaluronic acid gonarthritis . There , however , consensus best method . Regarding substance inject , corticosteroid alone exhibit rapid result , poor durability . Viscosupplementation show consistent result . However , especially use derivative high molecular weight hyaluronan , significant number patient present acute synovial reaction viscosupplementation specially first cycle three injection . The association triamcinolone injection hyaluronic acid decrease complaint first month treatment . Our objective evaluate best dosage viscosupplementation hyaluronic acid ( OSTEONIL® ) associate 1 ml ( 20 mg ) triamcinolone hexacetonide compare two group patient knee OA , first single application 3 ampoule second three application , one per week three week . One hundred four knee osteoarthritis ( KOA ) patient , currently usual care KOA Osteometabolic Group - Department Orthopedics Traumatology - University São Paulo General Hospital - assess . After sign informed consent , participant respond WOMAC™ , Lequesne™ , VAS , SF-36 ( quality life ) subjective IKDC ( International Knee Documentation Committee ) . The questionnaire functional assessment perform procedure infiltration 1month , 3 month , 6 month 1 year intervention.Twenty Patients submit evaluation use force platform balance NeuroCom ® , follow test : weight support squat ( weight bearing squat ( WBS ) , one-leg support ( unilateral stance ( U.S. ) , sit foot ( sit stand - STS ) . Previously , 1 month , 3 month , 6 month 12 month intervention . Frontal weight-bearing , profile axial radiograph perform radiologically assess participant ' knees.Patients randomly divide two group 54 patient , ( group 1 2 ) . Patients group 1 ( G1 ) submit viscosupplementation 1 application 3 vial hyaluronic acid 20mg/2ml ( OSTEONIL® ) 1 ml ( 20 mg ) triamcinolone , whereas group 2 patient submit viscosupplementation three application one ampoule hyaluronic acid 20 mg/2ml ( one per week three week ) , first application OSTEONIL® 1 ml ( 20 mg ) triamcinolone .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Met American College Rheumatology criterion hip osteoarthritis No knee intraarticular injection last 6 month Severe reaction procedure</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Viscosupplementation</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>